Role and inhibition of GLI1 protein in cancer

Eloise Mastrangelo
Mario Milani
CNR – Biophysics Institute, c/o Dipartimento di Bioscienze, Università degli Studi di Milano, Milano, Italy

Abstract: GLI1 is a transcriptional regulator involved in the development of different types of cancer. GLI1 transcriptional activity is regulated within the Hedgehog pathway (canonical activity), but can also be controlled independently (non-canonical activity) in the context of other signaling pathways. Experimental evidences show GLI1 involvement in both small- and non–small-cell lung cancers. Direct inhibition of the protein, in combination with other chemotherapeutic agents, represents a promising strategy for the treatment of different malignancies.

Keywords: Hedgehog pathway, transcriptional regulator, lung cancer, inhibitors

Introduction

GLI1 is a transcriptional factor component of the canonical and non-canonical Hedgehog (Hh) pathway. Hh signaling is evolutionarily conserved in Drosophila melanogaster and superior vertebrates. In mammals, three different Hh genes have been described as initiators of the signaling pathway: SHH, IHH, and DHH – each with a characteristic role and distribution. IHH and DHH have been shown to play important roles in normal tissue development, including bone formation and the pancreas, respectively. The SHH signaling pathway (initiated by the SHH glycoprotein) is the most studied, and it plays an essential role in the embryonic development required for appropriate cell differentiation and maintenance of tissue polarity.

SHH-mediated transduction is activated through the binding of SHH to the PTCH. PTCH, in the absence of the SHH ligands, inhibits the activity of seven-transmembrane G-protein-coupled receptor like Smoothened (SMO). After SHH binding, PTCH inhibition of SMO is released, with resultant phosphorylation and nuclear translocation of the zinc finger (ZF) glioma-associated transcription factors GLI1, GLI2, and GLI3, which are terminal effectors of SHH signaling (Figure 1).

Of these proteins, GLI1 and GLI2 mainly have a transcriptional activator function, whereas GLI3 acts as a transcriptional repressor. GLI targets include specific genes that regulate differentiation, proliferation, and survival. In particular, GLI1 can activate many downstream proteins such as SHH, PTCH, GLI1, and GLI2 as well as cell-cycle-regulating proteins, including the proto-oncogene N-myc and cyclin D.

The Hh pathway plays an important role in cell proliferation, differentiation, apoptosis, and migration, and it has been shown to cross talk with other signaling pathways such as MAPK/ERK, PI3K/AKT/mTOR, EGFR, and NOTCH.

It is not difficult to imagine that deregulation of the Hh pathway could contribute to tumorigenesis or accelerate the rate of tumor growth. Anomalous activation of...
the SHh pathway has been shown in many human cancers, including basal cell carcinoma (BCC), malignant gliomas, medulloblastoma, leukemias, and carcinomas of the breast, lung, pancreas, and prostate. Moreover, activated Hh signaling has been identified in cancer stem cells (CSCs) of numerous solid tumors (eg, glioblastoma, breast, colon, pancreatic, hepatocellular) and hematologic malignancies, and it has been shown to increase tumor-initiating populations and contribute to cell migration, clonogenicity, growth, and survival. Hh signaling has, furthermore, been shown to promote tumor metastasis and recurrence, likely through the induction of genes involved in the epithelial–mesenchymal transition (EMT).

SHh deregulation can occur by somatic mutations in upstream pathway elements (ligand independent), such as SMO and PTCH, or can be induced in a ligand-dependent manner, through enhanced autocrine or paracrine signaling. Moreover, multiple mechanisms have been involved in enhancing GLI protein activity in the absence of SHH ligands. Such non-canonical activation can occur through PTCH acting as a dependence receptor independently of SMO through regulation of cyclin D1 and caspase 9. Non-canonical activation of GLI1 and GLI2 by pathways orthogonal to the classical Shh pathway has been reported in a number of tumors, including loss of SMARCB1 in malignant rhabdoid tumors, K-ras and tumor growth factor beta (TGFβ) in pancreatic cancer, and PI3K in glioblastoma. Thus, GLI1 and GLI2 can also act as terminal effectors for numerous other oncogenic pathways.

In breast cancer, TGFβ signaling can activate GLI2 target genes, thereby causing enhanced bone metastasis. In BCC, mutated PTCH expression prevents a cellular response to the cell-cycle checkpoint cyclin B1 and promotes GLI activation. In Burkitt lymphoma, the oncogene c-MYC regulates GLI1 expression independently of SMO, PTCH, or the presence of Hh ligands. In a pancreatic cancer model, the Hh pathway is activated in a paracrine manner. Other signaling pathways, such as PI3K/AKT and RAS/ERK, can activate GLI proteins in different cancer types.

It is generally thought that specific inhibitors of the SHh pathway may provide an efficient therapy for a wide range of malignancies. Several Hh inhibitors have been developed so far, and their use has been integrated into the treatment of human carcinomas.

**GLI1 transcription factor**

GLI1 (1106 amino acids; MW 117.9 kDa) is a C2-H2-type ZF transcription factor, harboring five ZF domains (ZF1–5). ZF4 and ZF5 bind specifically to consensus sequence 5′-GACCACCCA-3′, whereas ZF1–3 interact with the phosphate backbone (Figure 2) and contribute to binding stability and recruitment of co-regulatory factors. The GLI1 C-terminal region (amino acids 1020–1091) has transactivating function through modulation of chromatin remodeling and is able to interact with histone acetyltransferase (HAT), histone deacetylase (HDAC), SWI-SNF5, and SWI/SNF-like Brg/Brm-associated factor. Such a region includes an acidic α-helix (amino acids 1037–1054) sharing 50% similarity with the herpes simplex viral protein 16 (VP16) transcription activation domain and hosts the three residues (Asp1040, Phe1048, and Leu1052) binding to the TFIID TATA box-binding protein-associated factor, TAFII31.

In breast cancer, TGFβ signaling can activate GLI2 target genes, thereby causing enhanced bone metastasis. In BCC, mutated PTCH expression prevents a cellular response to the cell-cycle checkpoint cyclin B1 and promotes GLI activation. In Burkitt lymphoma, the oncogene c-MYC regulates GLI1 expression independently of SMO, PTCH, or the presence of Hh ligands. In a pancreatic cancer model, the Hh pathway is activated in a paracrine manner. Other signaling pathways, such as PI3K/AKT and RAS/ERK, can activate GLI proteins in different cancer types.

It is generally thought that specific inhibitors of the SHh pathway may provide an efficient therapy for a wide range of malignancies. Several Hh inhibitors have been developed so far, and their use has been integrated into the treatment of human carcinomas.

**GLI1 transcription factor**

GLI1 (1106 amino acids; MW 117.9 kDa) is a C2-H2-type ZF transcription factor, harboring five ZF domains (ZF1–5). ZF4 and ZF5 bind specifically to consensus sequence 5′-GACCACCCA-3′, whereas ZF1–3 interact with the phosphate backbone (Figure 2) and contribute to binding stability and recruitment of co-regulatory factors. The GLI1 C-terminal region (amino acids 1020–1091) has transactivating function through modulation of chromatin remodeling and is able to interact with histone acetyltransferase (HAT), histone deacetylase (HDAC), SWI-SNF5, and SWI/SNF-like Brg/Brm-associated factor. Such a region includes an acidic α-helix (amino acids 1037–1054) sharing 50% similarity with the herpes simplex viral protein 16 (VP16) transcription activation domain and hosts the three residues (Asp1040, Phe1048, and Leu1052) binding to the TFIID TATA box-binding protein-associated factor, TAFII31.
Transcription of GLI proteins is regulated through phosphorylation, which occurs through the intermediary molecules IGUANA, protein kinase A (PKA), glycogen synthase kinase 3 beta (GSK3B), and casein kinase 1 alpha (CK1α), among others. Moreover, GLI transcription factors are inhibited by suppressor of fused (SUFU), which sequesters GLI proteins in the cytoplasm and abolishes their nuclear entry and transcriptional effects.

**GLI1-binding proteins**

The activity of GLI1 transcription factors can be limited by acetylation, via acetyltransferase p300. Indeed, GLI function can be restored by endogenous HDACs. In particular, HDAC1 and HDAC2 can form a complex with GLI1, as demonstrated by co-immunoprecipitation experiments. β-Arrestin1 (Arrb1) can suppress the transcriptional activity of GLI1 by potentiating its p300-mediated acetylation, and GLI1 protein levels sharply decrease in CSCs overexpressing Arrb1.

Overexpression of GLI1, either canonical or non-canonical, is very common in lung cancers. WW45 is a component of Hippo signaling pathway. Subcellular localization analysis of exogenously expressed WW45 and GLI1 (using immunofluorescence staining) demonstrated the co-localization of these two proteins. Moreover, overexpression of WW45 promotes the ubiquitination of GLI1 in a dose-dependent manner, suggesting that WW45 is able to inhibit Hh signaling by promoting the degradation of GLI1. Most importantly, overexpression of WW45 not only inhibits the growth and migration of lung cancer cells but also impairs de novo tumorigenesis of lung cancer that is driven by loss of liver kinase B1 (LKB1) and mutated Kras.

GLI1 is an effector of TGFβ signaling in the regulation of gene expression in cancer cells. Activation of the TGFβ pathway induces the formation of a complex between GLI1 and the transcription factor Sma- and Mad-related family member 4 (SMAD4) that is able to bind to the BCL2 promoter. SMAD4 depletion impairs complex formation and GLI1-mediated transcription of BCL2, leading to cell apoptosis.

Arginine N-methyltransferase 1 (PRMT1) methylates GLI1 at residue Arg597, promoting its transcriptional activity by enhancing its binding to target gene promoters. Abolishing GLI1 methylation attenuates its oncogenic functions and sensitizes pancreatic ductal adenocarcinoma (AD) cells to gemcitabine treatment.

USP21 is a centrosome-associated deubiquitylase (DUB) that is implicated in the formation of primary cilia – crucial organelles for the regulation of the Hh signaling pathway. USP21 is able to interact with GLI1, thereby suppressing GLI1-dependent transcription. In fact, USP21 recruits GLI1 to the centrosome, where it is negatively regulated through phosphorylation by PKA.

GLI1 binds to the C-terminal domain of the pluripotency factor NANOG. The N-terminus of NANOG, that contains a transcriptional repressor motif, inhibits GLI1-mediated transcriptional activation.

GLI1 interacts with 14-3-3c – a member of a family of evolutionarily conserved regulatory proteins capable of modulating the activity of the binding partner(s). These 14-3-3c proteins bind to phosphoserine/threonine-containing motifs through Lys49 – a critical residue in the phosphosubstrate-binding pocket. Only the wild-type 14-3-3c, but not the Lys49Glu mutant, is able to co-precipitate with GLI1, demonstrating that the interaction is phosphorylation dependent. Ser640 of GLI1 is crucial for the interaction with 14-3-3c, as proved by the Ser → Ala mutation. The sequence around Ser640 – RRXS – is the consensus phosphorylation sequence for PKA. Accordingly, PKA downregulates Hh signaling by inducing an interaction between GLI1 and 14-3-3c.

Finally, GLI1 can interact with the kinesin-like protein KIF7 together with serine/threonine-protein kinase 36 and with ZIC1, that enhances transcriptional activation.

**Hh pathway in cancer**

Unusual activation of the Hh pathway is related to the development of many types of cancer, and three different mechanisms have been proposed: type I, ligand-independent signaling due to protein mutations (eg, in BCC and medulloblastoma); type II, ligand-dependent signaling in autocrine or juxtacrine (mediated by cell–cell adhesion) way, dependent on overexpression of the SHH ligand (eg, in ovarian, colorectal, and pancreatic cancers); type III, ligand-dependent signaling in a paracrine manner, driven by overexpression of the SHH ligands by tumor cells that are received by the distant cells in the stroma and emit signals (like vascular endothelial growth factor [VEGF], insulin-like growth factor [IGF], etc.) back to the tumor to promote its growth and survival (eg, pancreatic, prostate, and colon cancers). Moreover in Type III, there is reverse paracrine signaling where the SHH ligand secreted by the stromal cells is received by the tumor cells. Type II or III patients may show effectiveness to antagonistic drugs that target the SHH ligand.

Glioblastoma multiforme (GBM) is the most common and a deadly brain cancer. It has been shown that the SMO
inhibitor cyclopamine (Cyp) can potentiate the effect of chemotherapy in GBM, reducing cell proliferation through attenuated GLI1 expression. The combination of Cyp with the chemotherapeutic agent temozolomide (TMZ) is effective in killing tumor parenchyma (TMZ effect) as well as the CSCs (Cyp effect) to resist tumor recurrence.

The SHh pathway can be regulated by ubiquitination. The deubiquitinase USP48 is able to interact directly with GLI1, cleaving off its ubiquitin and thus enhancing its lifetime. In GBM cells, knockdown of USP48 inhibits cell proliferation and expression of GLI1’s downstream targets, leading to repressed tumorigenesis. Such a mechanism is part of a positive feedback loop because USP48 expression is induced through GLI1-mediated transcriptional activation.

Cutaneous melanoma is the most aggressive form of skin cancer. GLI1 knockdown (KD) melanoma cell lines — established by using GLI1-targeting lentiviral short hairpin RNA — exhibit a markedly reduced invasion ability. GLI1 KD melanoma cells undergo a mesenchymal-to-epithelial-like transition, demonstrating that GLI1 is important for maintaining the invasive and mesenchymal-like properties of melanoma cells — most likely, by modulating EMT-inducing transcription factors.

Melanoma cell lines resistant to vemurafenib (a competitive kinase inhibitor) show increased levels of GLI1 and GLI2 as compared with naïve cells, with activation of the non-canonical Hh pathway, involving TGFβ/SMAD signaling. Knockdown of GLI1 and GLI2 as well as treatment with the GLI inhibitor GANT61 leads to a decreased invasion capability of melanoma cells and restores their sensitivity to vemurafenib.

In breast cancer models, EMT increases the metastatic capability of tumor cells in a paracrine way — in part, by non-cell autonomous activation of the GLI transcription factor. Treatment with the GLI inhibitor GANT61, but not with the SMO inhibitor IPI-926, inhibits growth in patient-derived xenograft (PDX) models.

These results clearly show that all Hh inhibitors may act against tumors with canonical Hh/GLI signaling, but only inhibitors directly targeting the GLI effectors can be useful against non-canonical EMT-induced GLI activation. Therefore, GLI antagonists are expected to more effectively inhibit Hh signaling in the context of heterogeneous breast cancers, restraining both primary tumor growth and metastasis.

Human embryonal tumors with multilayered rosette (ETMR) cells transplanted into host mice are susceptible to the inhibitor arsenic trioxide (ATO), demonstrating the driving role of the SHh pathway activation in the growth of ETMRs.

**Truncated GLI1 isoform (tGLI1) in cancer**

A novel alternative splice variant of GLI1, named the truncated GLI1 (tGLI1), originates from a deletion of 123 bases covering the entire exon 3 and part of exon 4 of the GLI1 gene. Expression of tGLI1 is undetectable in normal cells, but is high in GBM and other cancer cells. tGLI1 undergoes nuclear translocalization and is associated with increased motility and invasiveness of GBM cells. Moreover, tGLI1 expression is positively correlated with VEGF-C, tumor endothelial marker 7 (TEM7), and microvessel density, suggesting that tGLI1 could be a more potent transcriptional regulator than GLI1.

**GLI1 in lung cancers**

Lung cancers are malignancies that arise from epithelial cells (carcinomas). Currently, no effective treatment options exist for lung cancer, and the 5-year survival rate is ~14% for patients who receive the available treatment. Lung cancers are classified according to histologic type and therapeutic purposes into two broad classes: non-small-cell lung carcinoma (NSCLC; accounting for ~85% of all lung cancer cases), and small-cell lung carcinoma (SCLC; ~15%). The three main subtypes of NSCLC are AD (~40%), squamous cell carcinoma (SCC; ~30%), and large-cell carcinoma (~10%).

**Non-small-cell lung carcinoma**

In NSCLC, the deregulated SHh pathway with reactivation of GLI transcription factors facilitates the initiation, progression, and metastasis as well as confers drug resistance. Accordingly, inhibition of SHh signaling induces a significant decrease in the proliferation of NSCLC cells.

The role of SHh in NSCLC proliferation has been evaluated using A549 AD and H520 SCC cells (with AD and SCC being the first and second most frequent types of lung cancer, respectively). Both cells secrete the SHH ligand, which induces fibroblast proliferation, survival, migration, invasion, and collagen synthesis. Furthermore, SHH secreted by NSCLC stimulates the production of proangiogenic and metastatic factors in lung fibroblasts, demonstrating its important role in mediating epithelial/mesenchymal cross talk.

Accordingly, the blockage of the Hh pathway through SMO inhibition by cyclopamine reduces NSCLC proliferation and viability. Furthermore, upon silencing of the three
human GLI factors, GLI1 was demonstrated to be the major regulator of NSCLC cell proliferation, whereas GLI2 displays only a modest effect, and GLI3 slightly increases proliferation. Such evidences suggest that GLI1 and GLI2 have a redundant role in NSCLC cells, as observed in mice, where the absence of GLI2 can be compensated by GLI1. The role of GLI1 in NSCLC proliferation may be related to its main function as an activator of transcription.

High GLI1 mRNA expression correlates with worse overall survival of NSCLC patients (in particular, AD and SCC patients). Knockdown of GLI1 significantly inhibits anchorage-dependent liquid colony-forming ability in both the SCC cells – HCC95 and HCC2814 – compared with scrambled siRNA controls, suggesting that GLI1 is critical for lung SCC clonogenicity. Subcutaneous xenograft tumors of shGLI1 HCC95 cells grow significantly slower, exhibiting decreased expression of GLI1 mRNA. In contrast, the addition of SMO antagonists or other Hh pathway agonists does not affect GLI1 expression in lung SCC cells, indicating that GLI1 expression is independent of SHH ligands and SMO. In this case, GLI1 expression is regulated by the PI3K and MAPK pathways. Thus, a combinatorial therapeutic strategy capable of targeting the PI3K/mTOR pathway and GLI1 together may lead to effective outcomes for PI3K-pathway-dependent cancers, in contrast to recent results of human trials with a single PI3K antagonist. SCC cells treated with BEZ235 (PI3K/mTOR dual inhibitor), LY294002 (PI3K inhibitor), and U0126 (MEK1/2 inhibitor) show diminished levels of protein kinase B and pERK, together with decreased GLI1 protein levels. Indeed, BEZ235 significantly inhibits clonogenicity and proliferation of lung SCC cells. Moreover, CC95 cells treated with ATO (a Food and Drug Administration [FDA]-approved drug with sub-micromolar potency against GLI1/2) displays significantly reduced GLI1 mRNA and protein expression. In addition, through inhibition of GLI1, ATO strongly inhibits HCC95 colony-forming efficiency and cell proliferation as compared with controls. GLI1 expression in these PIK3CA-amplified SCC cell lines is critical for tumor growth, being regulated primarily by the PI3K pathway instead of the classical Hh pathway, and combinatorial inhibition of PI3K and GLI1 leads to tumor regression in vitro and in vivo.

NSCLC progression can be contrasted by the Chinese herb Scutellariae barbata D. Don (SBE). SBE can repress SHh signaling, thereby arresting cell-cycle progression and sensitizing lung cancer cells to the chemotherapeutic agent cisplatin in vitro and in vivo. Mechanistic investigations indicate that SBE specifically downregulates SMO and consequently attenuates the activities of GLI1 and its downstream targets, representing a promising novel drug candidate for NSCLC treatment.

Several homeobox-related gene (HOX) transcription factors such as mesenchyme HOX-2 (MEOX2) are associated with cancer drug resistance. MEOX2 can occupy the GLI1 gene promoter region from −2192 to −109, accompanied by transcriptionally active RNA Pol II, and is epigenetically linked to the active histones H3K27Ac and H3K4me3. MEOX2-dependent GLI1 protein expression is associated with disease progression and reduced survival rates. The overexpressed MEOX2–GLI1 axis is clinically correlated with cancer resistance to platinum-based drugs and tyrosine kinase inhibitors in patients with NSCLC.

GLI1 is expressed in ~76% of AD; however, in roughly half of these tumors, the activator of the canonical Hh pathway displays low expression levels. This feature is explained by the non-canonical activation of GLI1 by MAPK/ERK signaling. In this case, direct suppression of GLI1 – by RNA silencing or small-molecule inhibitors – prevents AD cell proliferation, attenuates stem-like properties, and increases their susceptibility to apoptosis in vitro and in vivo.

GLI1 expression in SCC – evaluated by immunohistochemistry in tissue specimens from patients – is significantly correlated with T-stage lymph node metastasis and reduced overall survival.

Small-cell lung carcinoma
The SCLC is an aggressive neuroendocrine subtype of lung cancer for which there is no effective treatment. The SHh pathway is activated in both neuroendocrine progenitor cells and SCLC cells in mice.

The crucial role of Hh signaling in the development and maintenance of SCLC suggests that Hh pathway inhibition could be a valuable therapeutic strategy to slow disease progression and delay cancer recurrence. The activation of Hh signaling has been reported in a subset of human SCLC cell lines and tumors without changes in Hh pathway gene copy numbers or no evidence of recurrent mutations. The Hh pathway is activated in SCLC cells by the constitutive activation of SMO independently of the lung microenvironment, promoting the clonogenicity of human SCLC in vitro and the initiation and progression of mouse SCLC in vivo. Treatment of mouse SCLC cell lines with inhibitors of GLI proteins HPI-1 and GANT61 reduces GLI1 levels and cell survival as compared to that with vehicle treatment, indicating that the Hh pathway is required for the maintenance of...
the disease. In particular, the Hh pathway is active in mouse SCLC cells through an autocrine–juxtacrine loop, and one crucial function of the pathway is to enhance survival.

A mouse model of SCLC demonstrates that the SHH ligand is crucial for disease progression. SHH overexpression activates canonical Hh signaling and markedly accelerates tumor progression, supporting an autocrine model of Hh signaling in SCLC pathogenesis.77 Furthermore, the non-canonical activation of Hh signaling is the cause of the chromosomal instability observed in SCLC.77

**GLI1 inhibitors**

The most common way to target SHH is to modulate SMO. However, the inhibition of the downstream effector GLI1 has been used to inhibit cell growth and promote apoptosis. A SHH inhibitor of particular importance is a monoclonal antibody directed at PTCH,78 but also small molecules such as GDC-0449 (Genentech), BMS-833923/XL139 (Exelixis/Bristol–Myers Squibb), LDE-225 (Novartis), IPI-926 (Infinity Pharmaceuticals), and SANT (Sigma Aldrich), as well as Bristol–Myers Squibb), LDE-225 (Novartis), IPI-926 (Infinity Pharmaceuticals), and SANT (Sigma Aldrich), as well as GDC-0449/vismodegib80) have received FDA approval for treating BCC, and many clinical trials are being conducted to evaluate the efficacy of this class of inhibitors in different cancers.

Several small-molecule inhibitors have been developed to suppress Hh signaling by blocking SMO, and nine SMO antagonists have already been evaluated in clinical trials.79 Cyclopamine — a natural steroid alkaloid derived from the plant *Veratrum californicum* — was the first identified SMO inhibitor. Many derivatives of cyclopamine have been developed to enhance specificity and pharmacologic potency. To date, two SMO inhibitors (LDE225/sonidegib and GDC-0449/vismodegib)80 have received FDA approval for treating BCC, and many clinical trials are being conducted to evaluate the efficacy of this class of inhibitors in different cancers.

Despite the encouraging clinical results in patients with medulloblastoma or BCC, in patients with extensive-stage SCLC, the addition of SMO inhibitors to standard chemotherapy does not appear to offer any additional benefit in terms of overall survival. Such results are related to the non-canonical, SMO-independent activation of GLI-mediated transcription by other signaling pathways,81 such as the neuropilin-2/ERK cascade (NRP2/ERK),82 K-Ras/ERK signaling,21 and the mTOR/S6K1 pathway.83

Because the GLI proteins are the final effectors of SHH and other important molecular pathways, the development of a GLI-targeted approach might be useful to downregulate many pro-proliferative, pro-survival, and pro-angiogenic genes, thereby inhibiting tumor growth and therapeutic resistance.

The library of GLI1 antagonists is not as extensive as that for SMO. Among GLI antagonists, there are GANT58 and GANT61 (GLI-ANTagonist).15 Both compounds have been identified in a cell-based screen for small-molecule inhibitors of GLI1-mediated transcription using HEK293 cells transiently expressing GLI1 and a GLI-dependent luciferase reporter.79 These two compounds belong to different chemical classes, with GANT61 being a hexahydropyrimidine derivative and GANT58 possessing a thiophene core with four pyridine rings. GANT61 is more specific toward GLI1 proteins and effectively reduces GLI1 and GLI2 DNA-binding ability, inhibiting the Hh pathway with a half maximal effective concentration (EC$_{50}$) of 5 μM in GLI1-expressing HEK293T cells. GANT61 binds to the GLI1 protein between ZF2 and ZF3, by interacting with Glu119 and Glu167, as demonstrated by in silico docking on the crystal structure of the ZF domain of GLI1 bound to DNA (PDB-ID 2GLI; Figure 2). Experimental analysis shows that mutation of the predicted binding sites significantly reduces GANT61-GLI binding affinity. The GANT61 binding site is different from the GLI DNA-binding region, and the inhibitor is not able to bind to other ZF transcription factors such as KLF4 or TFIIb.85

Cyclopamine, GANT58, and GANT61 are effective in suppressing tumor cell growth in nude mice injected with GLI1-positive 22Rv1 prostate cancer cells. Treatment with GANT58 inhibits additional growth of xenografted tumor size and with GANT61 induces complete tumor regression. During the 18-day treatment time, no adverse side effects were observed with either of the GANT compounds.86 No clinical trials are currently ongoing with either GANT58 or GANT61 to treat any type of cancer.

ATO is an FDA-approved inhibitor of GLI1 and GLI2 transcription factors, currently tested in several clinical trials ranging from Phase I to Phase IV for both solid tumors and hematologic malignancies, including lung cancers. Despite its in vitro cytotoxicity, in a recent clinical trial, ATO failed to show any in vivo efficacy against SCLC tumor growth.84

Numerous reports have demonstrated a tumor inhibitory effect of polyunsaturated fatty acids (PUFAs). The PUFA arachidonic acid (AA) is able to repress GLI1 expression by stimulating the nuclear translocation of nuclear factor of activated T cells 1 (NFATc1), which then binds the GLI1 promoter to repress its transcription.85

Glabrescione B (GlaB) – a natural isoflavone present in the seeds of *Derris glabrescens* – was identified on the basis of the crystal structure of the ZF domain of GLI1 in complex with DNA.86 GlaB is able to bind the GLI1 ZF domain,
interfering with its interaction with DNA and inhibiting GLI-dependent tumors and CSCs in vitro and in vivo. Such features indicate that direct interference of GLI/DNA interaction can be a valuable therapeutic strategy to control Hh pathway activation in cancer.

HPI-1 was identified with a high-throughput screening for compounds capable of abolishing the Hh target gene expression induced by the SMO agonist SAG. HPI-1 can suppress Hh pathway activation, likely through targeting a posttranslational modification of the GLI proteins and/or an interaction between the transcription factor and a co-factor.

Finally, solasonine – a glycoalkaloid found in Solanaceous plants – is able to inhibit the GLI-luciferase activity induced by ectopic expression of GLI1 or GLI2 with half-maximal inhibitory concentration (IC$_{50}$) values of 2.5 and 2.3 μM, respectively.

**Acknowledgment**
This work has been conducted with the support of the Italian Association for the Cancer Research (AIRC): “My First AIRC Grant (MFAG),” project code: 17083.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**


